Bahnassy AA, Zekri ARN, El-Bastawisy A, Fawzy A, Shetta M, Hussein N, Omran D, Ahmed AAS, El-Labbody SS. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease. World J Gastroenterol 2014; 20(48): 18240-18248 [PMID: 25561791 DOI: 10.3748/wjg.v20.i48.18240]
Corresponding Author of This Article
Abeer A Bahnassy, MD, PhD, Professor, Molecular Pathology Unit, Pathology Department, National Cancer Institute, Cairo University, Fom El Khalig, Cairo 11796, Egypt. chaya2000@hotmail.com
Research Domain of This Article
Biology
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 4 Expression of telomerase and melanoma antigen encoding genes n (%)
Gene
HCC (n = 70)
CH (n = 30)
Control (n = 33)
P value
χ2
Telomerase
+++
26 (37.14)
0 (0.00)
0 (0.00)
< 0.001
49.663
++
13 (18.57)
0 (0.00)
0 (0.00)
-
31 (44.29)
30 (100)
33 (100)
MAGE1
+++
9 (12.86)
0 (0.00)
0 (0.00)
< 0.001
55.246
++
33 (47.14)
0 (0.00)
0 (0.00)
-
28 (40.00)
30 (100)
33 (100)
MAGE3
+++
24 (34.29)
0 (0.00)
0 (0.00)
< 0.001
55.246
++
20 (28.57)
0 (0.00)
0 (0.00)
-
26 (37.14)
30 (100)
33 (100)
Table 5 Marker expression in relation to tumor stage and grade n (%)
Gene
Stage
Grade
Early (n = 18)
Late (n = 52)
P value
Low (n = 43)
High (n = 27)
P value
Telomerase
+++
2 (11.11)
24 (46.15)
0.019
8 (18.60)
18 (66.67)
< 0.001
++
6 (33.33)
7 (13.46)
11 (25.58)
2 (7.41)
-
10 (55.56)
21 (40.37)
24 (55.81)
7 (25.93)
MAGE1
+++
0 (0.00)
9 (17.31)
0.099
3 (6.98)
6 (22.22)
0.123
++
8 (44.44)
25 (48.08)
20 (46.51)
13 (48.15)
-
10 (55.56)
18 (34.62)
20 (46.51)
8 (29.63)
MAGE3
+++
2 (11.11)
22 (42.31)
< 0.001
6 (13.95)
18 (66.67)
< 0.001
++
13 (72.22)
7 (13.46)
19 (44.19)
1 (3.70)
-
3 (16.67)
23 (44.23)
18 (41.86)
8 (29.63)
CD133
+
0 (0.00)
28 (53.85)
< 0.001
9 (20.93)
19 (70.37)
< 0.001
-
18 (100.00)
24 (46.15)
34 (79.07)
8 (29.63)
CK19
+
10 (55.56)
52 (100.00)
< 0.001
35 (81.40)
27 (100.00)
< 0.017
-
8 (44.44)
0 (0.00)
8 (18.60)
0 (0.00)
CD90
+
6 (33.30)
31 (59.60)
0.015
9 (20.93)
19 (70.37)
< 0.001
-
12 (66.70)
11 (21.15)
34 (79.07)
8 (29.63)
Citation: Bahnassy AA, Zekri ARN, El-Bastawisy A, Fawzy A, Shetta M, Hussein N, Omran D, Ahmed AAS, El-Labbody SS. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease. World J Gastroenterol 2014; 20(48): 18240-18248